CAMBRIDGE, Mass., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Canaccord Genuity Growth Conference in Boston. Marc Beer, CEO of Aegerion, is scheduled to present on Tuesday, August 14 at 1:30 pm ET.
